Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
PHPhathom Pharmaceuticals, Inc. logo

Phathom Pharmaceuticals, Inc. (PHAT)

NASDAQ Global Select · Currency in USD
$5.74 ▼ -1.27 (-18.12%)
At close: Oct 23, 4:00 PM ET. Market closed.
$5.92 ▲ +0.18 (+3.13%)
After hours: Oct 23, 7:33 PM ET

Summary

Previous Close
$7.01
Open
$6.72
Day's Range
$5.01 – $6.76
52 Week Range
$5.01 – $18.31
Volume
4,861,997
Avg. Volume
1,309,883
Market Cap
$464.37M
Beta (5Y Monthly)
0.50
PE Ratio (TTM)
--
EPS (TTM)
-$1.18
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$16.50

Profile: Phathom Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
371
CEO
Steven L. Basta

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection.

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate $0.07 · Revenue est. $84.82M
DateEst.Actual
Jul 30, 2026-$0.18-$0.21Miss
Apr 30, 2026-$0.27-$0.37Miss
Feb 26, 2026-$0.32-$0.29Beat
Oct 30, 2025-$0.40-$0.41Miss
Aug 7, 2025-$0.76-$0.79Miss
May 1, 2025-$1.06-$1.07Miss

Analyst view

Consensus price target
$16.50 ▲ +187.5%
Range $10.00 – $22.00
Rating: Buy
Buy 89% · Hold 11% · Sell 0%

Similar stocks

Get free alerts on PHAT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.